Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 3/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.43 |
| ▸ | AGO2 | Q9UKV8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 5/20 | 0.41 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL883462 | 1.00 | TSHR (0.44) | TSHRLMNAMPOCYP3A4CYP2C9 | |
| SCHEMBL18148609 | 0.83 | F2 (0.42) | LMNAF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2300938 | 0.81 | GAA (0.43) | TSHRLMNAMPOCYP3A4CYP2C9 | |
| SCHEMBL10051833 | 0.80 | HSD11B1 (0.50) | LMNACYP3A4F2PRSS1PRSS2 | |
| SCHEMBL2301608 | 0.80 | HSD11B1 (0.50) | LMNACYP3A4F2PRSS1PRSS2 | |
| SCHEMBL23145884 | 0.80 | ATR (0.40) | ALDH1A1SMN1; SMN2CA1CA2ATR | |
| SCHEMBL20955611 | 0.79 | F2 (0.48) | TSHRLMNAMPOCYP3A4CYP2C9 | |
| SCHEMBL3468702 | 0.78 | CA12 (0.44) | TSHRCYP3A4F2PRSS1PRSS2 | |
| SCHEMBL835022 | 0.76 | ATR (0.37) | ALDH1A1CA1CA2CA12CA9 | |
| SCHEMBL883461 | 0.75 | TSHR (0.39) | TSHRLMNAMPOCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2021-03-11 | — | — | US | disclosed |
| EP-3604281-A1 | 2(1H)-QUINOLINONE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-02-05 | — | — | EP | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2350026-B1 | SULFOXIMINE SUBSTITUTED ANILINE PYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THEIR MANUFACTURE AND USE AS MEDICINE | BAYER IP GMBH (DE) | 2014-06-18 | — | — | EP | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-8735412-B2 | Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-01 | — | — | US | disclosed |
| EP-2350026-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010046035-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010046035-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-29 | — | — | WO | disclosed |
| EP-2179991-A1 | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
| EP-2179991-A1 | Sulfoximine substituted aniline pyrimidine derivatives as CDK inhibitors, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294838-A1 | SULFOXIMINE-SUBSTITUTED ANILINOPYRIMIDINE DERIVATIVES AS CDK INHIBITORS, THE PRODUCTION THEREOF, AND USE AS MEDICINE | CDK6, CDK4, CDK9 | TSHR 3216/4885LMNA 4343/4885MPO 2912/4885 |
| US-20210070747-A1 | 2(1H)-QUINOLINONE DERIVATIVE | TOP2A, TOP2B, TOP1 | TSHR 4265/4885LMNA 741/4885MPO 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.